{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T05:13:07Z","timestamp":1648876387195},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T00:00:00Z","timestamp":1133827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s00228-005-0059-x","type":"journal-article","created":{"date-parts":[[2005,12,5]],"date-time":"2005-12-05T16:19:04Z","timestamp":1133799544000},"page":"43-49","source":"Crossref","is-referenced-by-count":3,"title":["Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction"],"prefix":"10.1007","volume":"62","author":[{"given":"Lars","family":"Bjerrum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"key":"59_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1473-3099(01)00168-2","volume":"2","author":"M Leinonen","year":"2002","unstructured":"Leinonen M, Saikku P (2002) Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2:11\u201317","journal-title":"Lancet Infect Dis"},{"key":"59_CR2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/ejvs.1998.0757","volume":"17","author":"JS Lindholt","year":"1999","unstructured":"Lindholt JS, Fasting H, Henneberg EW, Ostergaard L (1999) A review of Chlamydia pneumoniae and atherosclerosis. Eur J Vasc Endovasc Surg 17:283\u2013289","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"59_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1469-0691.2002.00382.x","volume":"8","author":"J Ngeh","year":"2002","unstructured":"Ngeh J, Anand V, Gupta S (2002) Chlamydia pneumoniae and atherosclerosis \u2013 what we know and what we don't. Clin Microbiol Infect 8:2\u201313","journal-title":"Clin Microbiol Infect"},{"key":"59_CR4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0149-2918(02)85147-5","volume":"24","author":"JP Dugan","year":"2002","unstructured":"Dugan JP, Feuge RR, Burgess DS (2002) Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease. Clin Ther 24:719\u2013735","journal-title":"Clin Ther"},{"key":"59_CR5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1161\/01.CIR.96.2.404","volume":"96","author":"S Gupta","year":"1997","unstructured":"Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ (1997) Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96:404\u2013407","journal-title":"Circulation"},{"key":"59_CR6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/euhj.1998.1283","volume":"20","author":"E Gurfinkel","year":"1999","unstructured":"Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B (1999) Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 20:121\u2013127","journal-title":"Eur Heart J"},{"key":"59_CR7","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/01.CIR.102.15.1755","volume":"102","author":"JB Muhlestein","year":"2000","unstructured":"Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR et al (2000) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102:1755\u20131760","journal-title":"Circulation"},{"key":"59_CR8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/01.CIR.99.12.1540","volume":"99","author":"JL Anderson","year":"1999","unstructured":"Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C et al (1999) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 99:1540\u20131547","journal-title":"Circulation"},{"key":"59_CR9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(03)12706-7","volume":"361","author":"B Cercek","year":"2003","unstructured":"Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S et al (2003) Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 361:809\u2013813","journal-title":"Lancet"},{"key":"59_CR10","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/jama.290.11.1459","volume":"290","author":"CM O'Connor","year":"2003","unstructured":"O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S et al. (2003) Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290:1459\u20131466","journal-title":"JAMA"},{"issue":"Suppl 3","key":"59_CR11","first-page":"S669","volume":"84","author":"W Leowattana","year":"2001","unstructured":"Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M et al. (2001) Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 84 (Suppl 3):S669\u2013S675","journal-title":"J Med Assoc Thai"},{"key":"59_CR12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/01.CIR.0000012544.07696.1F","volume":"105","author":"J Sinisalo","year":"2002","unstructured":"Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J et al. (2002) Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 105:1555\u20131560","journal-title":"Circulation"},{"key":"59_CR13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1161\/01.CIR.0000027820.66786.CF","volume":"106","author":"AF Stone","year":"2002","unstructured":"Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J et al. (2002) Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106:1219\u20131223","journal-title":"Circulation"},{"key":"59_CR14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1161\/01.CIR.0000054613.57105.06","volume":"107","author":"R Zahn","year":"2003","unstructured":"Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M et al. (2003) Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 107:1253\u20131259","journal-title":"Circulation"},{"key":"59_CR15","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(00)05181-3","volume":"357","author":"F Neumann","year":"2001","unstructured":"Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C et al (2001) Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357:2085\u20132089","journal-title":"Lancet"},{"key":"59_CR16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1592\/phco.24.4.338.33181","volume":"24","author":"M Etminan","year":"2004","unstructured":"Etminan M, Carleton B, Delaney JA, Padwal R (2004) Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy 24:338\u2013343","journal-title":"Pharmacotherapy"},{"key":"59_CR17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.281.5.427","volume":"281","author":"CR Meier","year":"1999","unstructured":"Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H (1999) Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 281:427\u2013431","journal-title":"JAMA"},{"key":"59_CR18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00041433-200312000-00009","volume":"14","author":"JB Muhlestein","year":"2003","unstructured":"Muhlestein JB (2003) Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 14:605\u2013614","journal-title":"Curr Opin Lipidol"},{"key":"59_CR19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ahj.2003.09.011","volume":"147","author":"EV Gelfand","year":"2004","unstructured":"Gelfand EV, Cannon CP (2004) Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J 147:202\u2013209","journal-title":"Am Heart J"},{"issue":"Suppl 3","key":"59_CR20","doi-asserted-by":"crossref","first-page":"S563","DOI":"10.1086\/315604","volume":"181","author":"LA Jackson","year":"2000","unstructured":"Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM (2000) Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis 181[Suppl 3]:S563\u2013S565","journal-title":"J Infect Dis"},{"key":"59_CR21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3201\/eid0502.990216","volume":"5","author":"LA Jackson","year":"1999","unstructured":"Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM (1999) Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 5:281\u2013284","journal-title":"Emerg Infect Dis"},{"key":"59_CR22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0002-9149(01)02156-7","volume":"89","author":"JA Luchsinger","year":"2002","unstructured":"Luchsinger JA, Pablos-Mendez A, Knirsch C, Rabinowitz D, Shea S (2002) Relation of antibiotic use to risk of myocardial infarction in the general population. Am J Cardiol 89:18\u201321","journal-title":"Am J Cardiol"},{"key":"59_CR23","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.284.23.2998","volume":"284","author":"RM Herings","year":"2000","unstructured":"Herings RM, Leufkens HG, Vandenbroucke JP (2000) Acute myocardial infarction and prior antibiotic use. JAMA 284:2998\u20132999","journal-title":"JAMA"},{"key":"59_CR24","first-page":"445","volume":"44","author":"D Gaist","year":"1997","unstructured":"Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44:445\u2013448","journal-title":"Dan Med Bull"},{"key":"59_CR25","unstructured":"Danish Medicines Agency (2004) Drug statistics 1994\u20131999. Copenhagen, Denmark"},{"key":"59_CR26","unstructured":"Anonymous (1993) Guidelines for ATC classification. In: R\u00f8nning M, Sakshaug S (eds) WHO Collaborating Centre for Drug Statistics Methodology, Oslo"},{"key":"59_CR27","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (1999) ATC index with DDDs annually. WHO, Geneva, Switzerland"},{"key":"59_CR28","unstructured":"Stata Press (1999) STATA for Windows. Stata Statistical Software, Texas"},{"key":"59_CR29","first-page":"163","volume":"158","author":"HW Nielsen","year":"1996","unstructured":"Nielsen HW, Tuchsen F, Jensen MV (1996) Validity of the diagnosis \u201cessential hypertension\u201d in the National Patient Registry. Ugeskr Laeger 158:163\u2013167","journal-title":"Ugeskr Laeger"},{"key":"59_CR30","first-page":"308","volume":"152","author":"M Madsen","year":"1990","unstructured":"Madsen M, Balling H, Eriksen LS (1990) The validity of the diagnosis of acute myocardial infarction in 2 registries: the Heart Registry compared to the National Patient Registry. Ugeskr Laeger 152:308\u2013314","journal-title":"Ugeskr Laeger"},{"key":"59_CR31","first-page":"128","volume-title":"Modern epidemiology","author":"K Rothman","year":"1998","unstructured":"Rothman K, Greenland S (1998) Precision and validity in epidemiological studies. In: Rothman K, Greenland S (eds) Modern epidemiology. Lippincott-Raven, Philadelphia, pp 128\u2013129"},{"key":"59_CR32","first-page":"1204","volume":"48","author":"JA Wedzicha","year":"2003","unstructured":"Wedzicha JA, Donaldson GC (2003) Exacerbations of chronic obstructive pulmonary disease. Respir Care 48:1204\u20131213","journal-title":"Respir Care"},{"key":"59_CR33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00043798-199604000-00009","volume":"3","author":"CL Welin","year":"1996","unstructured":"Welin CL, Rosengren A, Wilhelmsen LW (19896) Social relationships and myocardial infarction: a case-control study. J Cardiovasc Risk 3:183\u2013190","journal-title":"J Cardiovasc Risk"},{"key":"59_CR34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ije\/27.3.410","volume":"27","author":"J Hallqvist","year":"1998","unstructured":"Hallqvist J, Lundberg M, Diderichsen F, Ahlbom A (1998) Socioeconomic differences in risk of myocardial infarction 1971\u20131994 in Sweden: time trends, relative risks and population attributable risks. Int J Epidemiol 27:410\u2013415","journal-title":"Int J Epidemiol"},{"key":"59_CR35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dkg072","volume":"51","author":"N Bruinsma","year":"2003","unstructured":"Bruinsma N, Hutchinson JM, van den Bogaard AE, Giamarellou H, Degener J, Stobberingh EE (2003) Influence of population density on antibiotic resistance. J Antimicrob Chemother 51:385\u2013390","journal-title":"J Antimicrob Chemother"},{"key":"59_CR36","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1086\/320718","volume":"183","author":"L Ostergaard","year":"2001","unstructured":"Ostergaard L, Sorensen HT, Lindholt J, Sorensen TE, Pedersen L, Eriksen T et al (2001) Risk of hospitalization for cardiovascular disease after use of macrolides and penicillins: a comparative prospective cohort study. J Infect Dis 183:1625\u20131630","journal-title":"J Infect Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0059-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-005-0059-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0059-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:19Z","timestamp":1558702279000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-005-0059-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,6]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1007\/s00228-005-0059-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,6]]}}}